Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real‐world setting

BACKGROUND AND AIM: Lenvatinib has been recently approved as a first‐line systematic therapy for patients with advanced hepatocellular carcinoma (HCC) based on the results of the phase 3 clinical trial REFLECT. This trial excluded patients with a history of systemic chemotherapy, bile duct invasion,...

Descripción completa

Detalles Bibliográficos
Autores principales: Sho, Takuya, Suda, Goki, Ogawa, Koji, Kimura, Megumi, Shimazaki, Tomoe, Maehara, Osamu, Shigesawa, Taku, Suzuki, Kazuharu, Nakamura, Akihisa, Ohara, Masatsugu, Umemura, Machiko, Kawagishi, Naoki, Natsuizaka, Mitsuteru, Nakai, Masato, Morikawa, Kenichi, Furuya, Ken, Baba, Masaru, Yamamoto, Yoshiya, Kobayashi, Tomoe, Meguro, Takashi, Saga, Akiyoshi, Miyagishima, Takuto, Yokoo, Hideki, Kamiyama, Toshiya, Taketomi, Akinobu, Sakamoto, Naoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008153/
https://www.ncbi.nlm.nih.gov/pubmed/32055698
http://dx.doi.org/10.1002/jgh3.12209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008153/
https://www.ncbi.nlm.nih.gov/pubmed/32055698
http://dx.doi.org/10.1002/jgh3.12209

Ejemplares similares